摘要
目的 观察超微量肝素治疗新生儿硬肿症的疗效及机制。方法 3 0例新生儿硬肿症患儿 ,随机分为肝素治疗组 ( 15例 )和治疗对照组 ( 15例 )。在综合治疗基础上 ,肝素治疗组加用肝素 ,每小时腹壁皮下缓慢注射 1次 ,每次每公斤体重 1U( 1mg =12 5U) ,疗程 1～ 3d。治疗前后检测血浆α颗粒膜蛋白 14 0 (GMP 14 0 )水平 ,并观察各组患儿症状和体征恢复正常时间。结果 治疗前 ,新生儿硬肿症各组血浆GMP 14 0均明显高于正常组 (P <0 .0 1) ;治疗后 ,肝素治疗组症状和体征恢复正常时间均比治疗对照组为早 (P <0 .0 1) ,同时GMP 14 0水平较治疗对照组显著下降 (P <0 .0 5 ) ,与正常组无差别 (P>0 .0 5 ) ,治疗对照组患儿GMP 14 0水平仍高于正常组 (P <0 .0 5 )。结论 新生儿硬肿症患儿存在血小板的活化 ,超微量肝素可抑制新生儿硬肿症患儿血小板活化功能的异常而改善症状 。
Objective To investigate the therapeutic effect and mechanism of ultramicroheparin on neonatal scleredema.Methods 30 cases of neonatal scleredema were randomly divided into two groups:the heparin treatment group (15 cases)and control treatment group (15 cases).On the basis of complex treatment,the patients in heparin treatment group were treated with heparin,1 U/kg (1 mg=125 U),slowly abdomonal subcutaneous injection,once a hour;the patients in control treatment group were treated by routine complex treatment,with a treatment course of 1～3 days for both groups.15 healthy neonates were served as normal control group.Results The level of plasma granule membrane protein 140 (GMP 140) in patients with neonatal scleredema was significantly higher than that in nonrmal control group (P<0.01).After treatment,GMP 140 level decreased significantly in heparin treatment group,as compared with that in control treatment group (P<0.05).The time that patients'symptoms and signs returned to normal state was obviously earlier in heparin treatment group than that in control treatment group (P< 0.01). Conclusion There is elveated platelet activation in neonatal scleredema,and ultramicroheparin may inhibit the activation of platelet,therefore improve the symoptoms and cut off the development of neonatal scleredema.
出处
《河北医药》
CAS
2003年第7期485-486,共2页
Hebei Medical Journal
